[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413542":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":19,"id":47,"slug":19,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-arterial administration of 3-n-butylphthalide","EXPERIMENTAL","Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug\u002Fmin.",[13],"Drug: Intra-arterial administration of neuroprotective agents",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Intra-arterial administration of neuroprotective agents",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Hui-Sheng T Chen, Ph.D.","CONTACT","+8613352452086","chszh@aliyun.com",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Department of Neurology, General Hospital of Northern Theater Command","RECRUITING","Shenyang","110016","China",{"type":34,"coordinates":35},"Point",[36,37],123.43278,41.79222,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":42,"phoneExt":19,"email":25},"Hui-Sheng Chen, Ph.D.","+86 13352452086",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Hui-Sheng Chen","Director","100413542",false,"NCT04664946","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Major neurologic deficits: 6≤NIHSS≤20;\n3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);\n4. Premorbid mRS 0 or 1;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Patients who underwent intravenous thrombolysis or Endovascular treatment;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\\u003C80000\u002Fmm3;\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n6. Unsuitable for this clinical studies assessed by researcher.","ALL","18 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"NA","To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.",[63,64],"Ischemic Stroke","Neuroprotection","2025-08-20",{"date":67,"type":68},"2025-08-21","ACTUAL",{"date":70,"type":68},"2020-12-01",{"date":72,"type":57},"2026-05-01",{"name":45,"class":6},1]